Literature DB >> 3221244

Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus.

R J Marttila1, H Lorentz, U K Rinne.   

Abstract

Oxygen-derived toxicity has been suggested as being involved in the pathogenesis of Parkinson's disease. Superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase provide the enzymatic defence against oxygen toxicity. The activities of these enzymes were measured in peripheral blood leucocytes, cerebrospinal fluid and in different brain regions from patients with idiopathic Parkinson's disease and from controls. There was no indication of a generalized defect in any of these enzymes in Parkinson's disease. The brain activities of catalase, glutathione peroxidase and glutathione reductase were also comparable to those of the controls. An increased superoxide dismutase-like activity was observed in several regions of parkinsonian brains, including the temporal cortex, thalamus and red nucleus. However, the most pronounced increase occurred in the substantia nigra and basal nucleus. This may be due to an increase of the superoxide dismutase activity or be a result of the presence of a compound with superoxide dismutase-like activity, and may reflect the involvement of radical-induced cell damage in the pathogenesis of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221244     DOI: 10.1016/0022-510x(88)90108-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  35 in total

1.  Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.

Authors:  M E Götz; C R Malz; A Dirr; D Blum; W Gsell; S Schmidt; R Burger; S Pohli; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2005-01-31       Impact factor: 3.575

2.  Glutathione peroxidase in early and advanced Parkinson's disease.

Authors:  P Johannsen; G Velander; J Mai; E B Thorling; E Dupont
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

3.  Serum antioxidant enzyme activity in Parkinson's disease.

Authors:  J Kalra; A H Rajput; S V Mantha; K Prasad
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

Review 4.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

5.  Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.

Authors:  Vedad Delic; Jeddidiah W D Griffin; Sandra Zivkovic; Yumeng Zhang; Tam-Anh Phan; Henry Gong; Dale Chaput; Christian Reynes; Vinh B Dinh; Josean Cruz; Eni Cvitkovic; Devon Placides; Ernide Frederic; Hamed Mirzaei; Stanley M Stevens; Umesh Jinwal; Daniel C Lee; Patrick C Bradshaw
Journal:  Neuromolecular Med       Date:  2017-06-15       Impact factor: 3.843

Review 6.  Mitochondrial proteostasis in the context of cellular and organismal health and aging.

Authors:  Erica A Moehle; Koning Shen; Andrew Dillin
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

Review 7.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 9.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

Review 10.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.